Uncompensated Care Costs

Unpacking the 340B Drug Pricing Program, Its Impact on the Pharmaceutical Industry

November 9, 2022 - The 340B Drug Pricing Program has evolved significantly since its establishment in 1992. According to an article published by the Commonwealth Fund, the 340B Program is a federal drug pricing program that allows certain hospitals, clinics, and healthcare facilities to buy drugs at a discounted rate. The discount ranges from 25 to 50%. The program predominantly covers facilities that...

Read More


More Articles

Drug Costs Are Not Justified by Research and Development Costs

by Veronica Salib

It’s no secret that drug costs in the United States have continued to increase in the past few years. The Kaiser Family Foundation states that between 2019 and 2022, 48% of prescription drugs had...

Gates Foundation Funds Refillable Birth Control Development

by Veronica Salib

The Bill and Melinda Gates Foundation recently granted $625,803 to Celanese — a chemical company focused on chemical intermediates, engineered materials, polymers, emulsions, and specialty food ingredients — to research and...

Understanding the Burdens of Dialysis

by Veronica Salib

Chronic kidney disease (CKD) occurs when the kidneys fail to filter waste as they typically do in a healthy body. Patients in the late stage of chronic kidney disease progress to end-stage renal failure (ESRF) when they need a transplant...

How EHR-Based Clinical Trials Can Accelerate Research Strategies

by Samantha McGrail

EHR-based clinical trials can accelerate the pace of research discoveries and generate sufficient evidence to inform treatment strategies, according to a recent article from the Clinical Journal...

Recent Articles